Although in some cases it may be possible to differentiate between malignant and benign tumors using molecular markers, the low sensitivity of tests to detect HCC via serum alpha-fetoprotein (AFP) limits clinical decision making [5]. The gene discussed is AFP; the disease is hepatocellular carcinoma.